Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma

Butt, Omar H.; Zhou, Alice; Huang, Jiayi; Leidig, William A; Silberstein, Alice E.; Chheda, Milan G.; Johanns, Tanner M.; Ansstas, George; Liu, Jingxia; Talcott, Grayson; Nakiwala, Ruth; Shimony, Joshua S.; Kim, Albert H.; Leuthardt, Eric C.; Tran, David; Campian, Jian

doi:10.1093/noajnl/vdac042

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To date, a phase II study of 41 patients with glioblastoma undergoing LITT combined with 20 mg/m 2 IV doxorubicin is the only trial that evaluated the safety and efficacy of this novel technique [ 94 ]. Authors reported higher overall survival (OS) compared to historical controls treated with bevacizumab or LITT with standard salvage chemotherapy [ 125 ]. However, it remains unclear to what extent the therapeutic benefit was attributed to the cytoreductive properties of LITT and the increased uptake of doxorubicin through disrupted BBB/BTB.…”

Section: Resultsmentioning

confidence: 99%

“…Satisfactory results coming from this trial support the combination of LITT with other chemotherapeutics; however, given that the authors reported poor CNS penetration of doxorubicin distal to the laser catheter, LITT may be a suitable method of BBBD in nodular, compact lesions rather than highly infiltrative HGGs [ 125 ].…”

Section: Resultsmentioning

confidence: 99%

“…poor drug penetration in CNS distal to the laser catheter [125]. • allows for repeated drug penetration to the brain parenchyma (albumin-bound paclitaxel plus carboplatin) [160].…”

mentioning

confidence: 99%

See 2 more Smart Citations

Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood–Brain Barrier Disruption

Pinkiewicz,

Walecki

et al. 2024

Cancers

View full text Add to dashboard Cite

The blood–brain barrier (BBB) poses a significant challenge to drug delivery for brain tumors, with most chemotherapeutics having limited permeability into non-malignant brain tissue and only restricted access to primary and metastatic brain cancers. Consequently, due to the drug’s inability to effectively penetrate the BBB, outcomes following brain chemotherapy continue to be suboptimal. Several methods to open the BBB and obtain higher drug concentrations in tumors have been proposed, with the selection of the optimal method depending on the size of the targeted tumor volume, the chosen therapeutic agent, and individual patient characteristics. Herein, we aim to comprehensively describe osmotic disruption with intra-arterial drug administration, intrathecal/intraventricular administration, laser interstitial thermal therapy, convection-enhanced delivery, and ultrasound methods, including high-intensity focused and low-intensity ultrasound as well as tumor-treating fields. We explain the scientific concept behind each method, preclinical/clinical research, advantages and disadvantages, indications, and potential avenues for improvement. Given that each method has its limitations, it is unlikely that the future of BBB disruption will rely on a single method but rather on a synergistic effect of a combined approach. Disruption of the BBB with osmotic infusion or high-intensity focused ultrasound, followed by the intra-arterial delivery of drugs, is a promising approach. Real-time monitoring of drug delivery will be necessary for optimal results.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood–Brain Barrier Disruption

Pinkiewicz,

Walecki

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Currently, there are multiple studies investigating the possibility of multimodal treatment in combination with LITT to provide synergistic delivery of other therapeutics to the tumor microenvironment [ 27 , 28 , 29 , 30 , 31 ]. Beyond just directed tumor cell death, LITT is also hypothesized to decrease the stability of tight junctions and the rate of transcytosis across the blood–blood–brain barrier (BBB) [ 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis

Pandey,

Chandla,

Mekonnen

et al. 2024

Cancers

View full text Add to dashboard Cite

Although primary studies have reported the safety and efficacy of LITT as a primary treatment in glioma, they are limited by sample sizes and institutional variation in stereotactic parameters such as temperature and laser power. The current literature has yet to provide pooled statistics on outcomes solely for primary brain tumors according to the 2021 WHO Classification of Tumors of the Central Nervous System (WHO CNS5). In the present study, we identify recent articles on primary CNS neoplasms treated with LITT without prior intervention, focusing on relationships with molecular profile, PFS, and OS. This meta-analysis includes the extraction of data from primary sources across four databases using the Covidence systematic review manager. The pooled data suggest LITT may be a safe primary management option with tumor ablation rates of 94.8% and 84.6% in IDH-wildtype glioblastoma multiforme (GBM) and IDH-mutant astrocytoma, respectively. For IDH-wildtype GBM, the pooled PFS and OS were 5.0 and 9.0 months, respectively. Similar to rates reported in the prior literature, the neurologic and non-neurologic complication rates for IDH-wildtype GBM were 10.3% and 4.8%, respectively. The neurologic and non-neurologic complication rates were somewhat higher in the IDH-mutant astrocytoma cohort at 33% and 8.3%, likely due to a smaller cohort size.

show abstract

Corrigendum to: A phase II study of laser interstitial thermal therapy combined with doxorubicin in patients with recurrent glioblastoma

Cited by 2 publications

References 0 publications

Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood–Brain Barrier Disruption

Breaking Barriers in Neuro-Oncology: A Scoping Literature Review on Invasive and Non-Invasive Techniques for Blood–Brain Barrier Disruption

Safety and Efficacy of Laser Interstitial Thermal Therapy as Upfront Therapy in Primary Glioblastoma and IDH-Mutant Astrocytoma: A Meta-Analysis

Contact Info

Product

Resources

About